Jpmorgan Chase & CO Acurx Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Shares
1 transactions
Others Institutions Holding ACXP
# of Institutions
26Shares Held
1.25MCall Options Held
9.3KPut Options Held
9.7K-
Vanguard Group Inc Valley Forge, PA529KShares$434,0660.0% of portfolio
-
Prospect Financial Services LLC Melville, NY295KShares$241,9610.35% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$120,1300.0% of portfolio
-
Morgan Stanley New York, NY46.2KShares$37,8840.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC44.8KShares$36,7190.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $9.48M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...